88 related articles for article (PubMed ID: 7198291)
41. [Combination chemotherapy with cyclophosphamide, adriamycin, cisplatin, nimustine, and methotrexate (EACAM) in advanced adenocarcinoma of the lung].
Nakanishi F; Mogi H; Sugiishi M; Sugiura I; Ogasawara T; Kinoshita T; Hoshino A
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3413-8. PubMed ID: 3466573
[TBL] [Abstract][Full Text] [Related]
42. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
43. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.
Debaere D; Vander Poorten V; Nuyts S; Hauben E; Schoenaers J; Schöffski P; Clement PM
B-ENT; 2011; 7(1):1-6. PubMed ID: 21563549
[TBL] [Abstract][Full Text] [Related]
44. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin.
Fiore JJ; Kelsen DP; Gralla RJ; Casper ES; Magill G; Cheng E; Ochoa M
Cancer Treat Rep; 1985 Jun; 69(6):591-4. PubMed ID: 4016765
[TBL] [Abstract][Full Text] [Related]
45. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA; Kolhouse JF; Klahr C
Cancer; 1976 Feb; 37(2):620-8. PubMed ID: 1253101
[TBL] [Abstract][Full Text] [Related]
46. Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung.
Eagan RT; Frytak S; Ingle JN; Creagan ET; Nichols WC; Kvols LK
Cancer Treat Rep; 1980; 64(8-9):925-8. PubMed ID: 7192602
[TBL] [Abstract][Full Text] [Related]
47. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract][Full Text] [Related]
48. Combination chemotherapy with adriamycin and cis-diamminedichloroplatinum in patients with neoplastic diseases.
Vogl S; Ohnums T; Perloff M; Holland JF
Cancer; 1976 Jul; 38(1):21-6. PubMed ID: 985619
[TBL] [Abstract][Full Text] [Related]
49. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
50. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin.
Dreyfuss AI; Clark JR; Fallon BG; Posner MR; Norris CM; Miller D
Cancer; 1987 Dec; 60(12):2869-72. PubMed ID: 2824016
[TBL] [Abstract][Full Text] [Related]
51. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
Lorenz M; Müller HH
J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
[TBL] [Abstract][Full Text] [Related]
52. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
Shildt RA; Kennedy PS; Chen TT; Athens JW; O'Bryan RM; Balcerzak SP
Cancer Treat Rep; 1983 Jan; 67(1):77-9. PubMed ID: 6616495
[TBL] [Abstract][Full Text] [Related]
53. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
Evans WK; Feld R; DeBoer G; Osoba D; Curtis JE; Baker MA; Myers RE; Quirt IC; Pritchard KI; Brown TC; Kutas GJ; Blackstein ME; Ottema B; Millband L
Cancer Treat Rep; 1981; 65(11-12):947-54. PubMed ID: 7028256
[TBL] [Abstract][Full Text] [Related]
54. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
55. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
56. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): preliminary assessment of a one-day vs. three-day drug regimen.
Creagan ET; Fleming TR; Edmonson JH; Ingle JN; Woods JE
Cancer; 1981 Jun; 47(11):2549-51. PubMed ID: 7196281
[TBL] [Abstract][Full Text] [Related]
58. Thymoma. A retrospective study of 87 cases.
Park HS; Shin DM; Lee JS; Komaki R; Pollack A; Putnam JB; Cox JD; Hong WK
Cancer; 1994 May; 73(10):2491-8. PubMed ID: 8174044
[TBL] [Abstract][Full Text] [Related]
59. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma.
Haas GP; Klugo RC; Hetzel FW; Barton EE; Cerny JC
J Urol; 1984 Oct; 132(4):828-33. PubMed ID: 6540817
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
